JP2012522764A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522764A5
JP2012522764A5 JP2012503351A JP2012503351A JP2012522764A5 JP 2012522764 A5 JP2012522764 A5 JP 2012522764A5 JP 2012503351 A JP2012503351 A JP 2012503351A JP 2012503351 A JP2012503351 A JP 2012503351A JP 2012522764 A5 JP2012522764 A5 JP 2012522764A5
Authority
JP
Japan
Prior art keywords
oxadiazol
dichloro
active pharmaceutical
pharmaceutical ingredient
stable composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012503351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522764A (ja
JP5864410B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/PT2010/000015 external-priority patent/WO2010114405A2/en
Publication of JP2012522764A publication Critical patent/JP2012522764A/ja
Publication of JP2012522764A5 publication Critical patent/JP2012522764A5/ja
Application granted granted Critical
Publication of JP5864410B2 publication Critical patent/JP5864410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012503351A 2009-04-01 2010-03-31 ニトロカテコール誘導体を含む医薬製剤及びその製造方法 Active JP5864410B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16579409P 2009-04-01 2009-04-01
US61/165,794 2009-04-01
PCT/PT2010/000015 WO2010114405A2 (en) 2009-04-01 2010-03-31 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015168153A Division JP6336420B2 (ja) 2009-04-01 2015-08-27 ニトロカテコール誘導体を含む医薬製剤及びその製造方法

Publications (3)

Publication Number Publication Date
JP2012522764A JP2012522764A (ja) 2012-09-27
JP2012522764A5 true JP2012522764A5 (https=) 2013-05-16
JP5864410B2 JP5864410B2 (ja) 2016-02-17

Family

ID=42229943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503351A Active JP5864410B2 (ja) 2009-04-01 2010-03-31 ニトロカテコール誘導体を含む医薬製剤及びその製造方法
JP2015168153A Active JP6336420B2 (ja) 2009-04-01 2015-08-27 ニトロカテコール誘導体を含む医薬製剤及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015168153A Active JP6336420B2 (ja) 2009-04-01 2015-08-27 ニトロカテコール誘導体を含む医薬製剤及びその製造方法

Country Status (15)

Country Link
US (3) US20100256194A1 (https=)
EP (1) EP2413913B1 (https=)
JP (2) JP5864410B2 (https=)
KR (1) KR101824257B1 (https=)
CN (2) CN105816456A (https=)
AU (1) AU2010231962B2 (https=)
BR (1) BRPI1016132B8 (https=)
CA (1) CA2757418C (https=)
DK (1) DK2413913T3 (https=)
ES (1) ES2915698T3 (https=)
MX (1) MX361618B (https=)
PL (1) PL2413913T3 (https=)
PT (1) PT2413913T (https=)
RU (1) RU2550133C2 (https=)
WO (1) WO2010114405A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) * 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
NO2699580T3 (https=) 2014-01-24 2018-02-24
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ,エス.アー. パーキンソン病を遅延させるための医薬
KR20200100075A (ko) * 2017-12-18 2020-08-25 유니켐 레버러토리스 리미티드 오피카폰 및 그의 중간체의 제조방법
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-{(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸}-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP3860602A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
AU2021235850A1 (en) 2020-03-13 2022-10-06 BIAL - PORTELA & Cª, S.A. Micronised opicapone
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
JP2024500754A (ja) 2020-12-17 2024-01-10 ビアル-ポルテラ エ コンパニア,ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン
US20240300930A1 (en) * 2021-02-26 2024-09-12 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
GB202212082D0 (en) 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
EP4719374A1 (en) 2023-05-25 2026-04-08 Bial-Portela & CA, S.A. Treatment regimens for early idiopathic parkinson's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) * 1921-07-25 1925-04-07 Louis A Godbold Lubricator
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4085563A (en) * 1977-01-31 1978-04-25 Campbell Soup Company Cookie dispensing apparatus
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4368668A (en) * 1981-05-15 1983-01-18 Veb Kombinat Polygraph "Werner Lamberz" Leipzig Printing plate mounting arrangement
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US6206110B1 (en) * 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
WO2000017175A1 (en) * 1998-09-18 2000-03-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ES2334888T3 (es) * 2000-11-28 2010-03-17 Zymogenetics, L.L.C. Receptor de citocina zcytor19.
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
KR100891887B1 (ko) * 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제
KR20040004705A (ko) * 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
EP1581213A4 (en) * 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
ES2933479T3 (es) * 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
US7300406B2 (en) * 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7531556B2 (en) * 2004-04-28 2009-05-12 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20080051441A1 (en) * 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
US7553964B2 (en) * 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) * 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
AR058439A1 (es) * 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
US20070048384A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
JP2008162955A (ja) * 2006-12-28 2008-07-17 Chugai Pharmaceut Co Ltd バリン含有高密度顆粒剤
EP2481410B1 (en) * 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
KR20110002462A (ko) * 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형

Similar Documents

Publication Publication Date Title
JP2012522764A5 (https=)
HRP20160450T1 (hr) Novi inhibitori reduktaze s-nitrozoglutationa
JP2016515582A5 (https=)
JP2019517455A5 (https=)
SI2576523T1 (sl) Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida
RU2013139662A (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
JP2013519680A5 (https=)
JP2014510132A5 (https=)
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
RU2011143619A (ru) Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
DK2073805T3 (da) Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
JP2008526866A5 (https=)
ME00681B (me) Jedinjenje indola
JP2011037901A5 (https=)
JP2013501720A5 (https=)
HRP20151405T1 (hr) Novi supstituirani kinolinski spojevi kao inhibitori reduktaze s-nitrosoglutationa
TR201908590T4 (tr) Nitrokatekol türevlerini içeren farmasötik formülasyonlar ve bunların üretimine yönelik yöntemler.
JP2015512931A5 (https=)
JP2010265321A5 (https=)
RU2014122035A (ru) Соединения с нематоцидной активностью
NZ602125A (en) Uses of dgat1 inhibitors
JP2010116404A5 (https=)
JP2013510216A5 (https=)
CY1125531T1 (el) Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της
SG10201407430TA (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate